Clinical Trial Update: Personalized Prophylactic Treatment With Advate® in Severe or Moderate Haemophilia A Patients

View source ↗

Summary

Clinical trial update examining personalized prophylactic treatment with Advate (factor VIII recombinant) for people with severe or moderate Hemophilia A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• ADVATE (antihemophilic factor VIII)

Snippet

Sponsor: Hospital Universitario La Fe | Conditions: Hemophilia A, Factor VIII | Status: UNKNOWN